SELLAS Life Sciences Group, Inc. Peo Total Comp Amt
SELLAS Life Sciences Group, Inc. (SLS) reported Peo Total Comp Amt of $1.88 million for the 12-month period ending 2025-12-31, per its DEF 14A filed 2026-04-23.
Financial Statements › Notes
ecd:PeoTotalCompAmt · last filed 2026-04-23
| Period end | Peo Total Comp Amt 12 month |
|---|---|
| 2025-12-31 | $1.88M DEF 14A · filed 2026-04-23 |
| 2024-12-31 | $1.19M DEF 14A · filed 2026-04-23 |
| 2023-12-31 | $1.75M DEF 14A · filed 2026-04-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |